Streetbeat News

Earnings

APRE

Aprea Therapeutics reported Q3 losses of $(0.86) per share, beating the analyst consensus estimate of $(1.16) by 25.86%. This is a 64.17% increase over losses from the same period last year. The company also reported quarterly sales of $319.47K, beating the analyst consensus estimate of $80.00K by 299.34%.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:27 pm

AVPT

AvePoint reported Q3 earnings per share (EPS) of $(0.02), a 50% improvement from $(0.04) last year. The company's quarterly sales were $72.76M, beating the analyst consensus estimate of $69.01M by 5.43% and marking a 15.97% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:27 pm

TMCI

Treace Medical Concepts Inc (NASDAQ:TMCI) reported worse-than-expected Q3 results and lowered its full-year 2023 revenue guidance below estimates. The company reported earnings losses of 28 cents per share, missing the analyst consensus estimate of losses of 26 cents. Quarterly sales were $40.76 million, missing the analyst consensus estimate of $42.05 million. The company lowered its full-year revenue guidance from between $191 million and $197 million to between $182 million and $186 million.

Portfolio Pulse from Ryan Gustafson

November 09, 2023 | 10:27 pm

VRRM

Verra Mobility has updated its FY23 adjusted EPS from $1-$1.10 to $1.05-$1.10, compared to the estimated $1.07. The company also revised its revenue forecast from $800M-$810M to the upper-end of the prior range, against the estimated $806.16M.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:26 pm

CURLF

Curaleaf Holdings, Inc. (OTC:CURLF) reported Q3 2023 financial results, with $333 million in revenue, up 2% YoY, and an adjusted EBITDA margin of 23%. The company's gross profit was $150.1 million, reflecting a 45% gross margin. The net loss was $92.3 million, or $0.13 per share, but the adjusted net loss from continuing operations was $70.8 million, or $0.10 per share. The company ended the quarter with $118.1 million in cash and generated $33.4 million in free cash flow.

Portfolio Pulse from Nicolás Jose Rodriguez

November 09, 2023 | 10:26 pm

ADVM

Adverum Biotechnologies reported Q3 losses of $(0.33) per share, missing the analyst consensus estimate of $(0.32) by 3.13 percent. However, this is a 17.5 percent increase over losses of $(0.40) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:26 pm

CANO

Cano Health (NYSE:CANO) reported Q3 2023 GAAP EPS of $(91.87), missing the estimate of $(18.50) by 396.59%. This is a 39843.48% decrease from the same period last year. However, the company's quarterly sales of $788.07M beat the estimate of $757.20M by 4.08%, marking an 18.51% increase from last year.

Portfolio Pulse from saritha@benzinga.com

November 09, 2023 | 10:25 pm

VRRM

Verra Mobility (NASDAQ:VRRM) reported Q3 earnings of $0.29 per share, beating the analyst consensus estimate of $0.27 by 7.41%. This is a 7.41% increase from the same period last year. The company also reported quarterly sales of $209.90 million, beating the analyst consensus estimate of $208.97 million by 0.45%. This is a 6.19% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:25 pm

PLRX

Pliant Therapeutics (NASDAQ:PLRX) reported Q3 losses of $(0.70) per share, beating the analyst consensus estimate of $(0.77) by 9.09%. However, this is a 7.69% increase in losses compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:24 pm

ONTO

Onto Innovation has projected its Q4 revenue to be between $200M and $216M, with an adjusted EPS of $0.90 to $1.10.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:24 pm